About Us

Gemmus Pharma is an early stage biotechnology company founded in 2007 to commercialize licensed technology and compounds that have been in development for many years as new therapeutics for infectious disease. Gemmus Pharma has received support from the NIH-NIAID and private investment. Gemmus is in the process of raising a seed round to fund submission of GP1001 as an investigational new drug (IND) for treatment of influenza infections to the FDA.